SCHEMBL25489016

SCHEMBL25489016

COCCCN(CCCOC)C(=O)OC(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 2/20 0.51
HDAC6 Q9UBN7 3/20 0.38
HDAC1 Q13547 3/20 0.38
HDAC2 Q92769 2/20 0.38
ALDH1A1 P00352 2/20 0.35
L3MBTL1 Q9Y468 4/20 0.34
MAPK1 P28482 1/20 0.33
SSTR4 P31391 1/20 0.33
TSHR P16473 1/20 0.32
DGAT1 O75907 1/20 0.32
HDAC3 O15379 1/20 0.32
NCOR2 Q9Y618 1/20 0.32
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA7 P43166 1/20 0.31
MLNR O43193 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31407326 0.88 CA14 (0.42) CA14HDAC6HDAC1HDAC2ALDH1A1
SCHEMBL22863885 0.86 CA14 (0.58) CA14ALDH1A1TSHRCA12CA1
SCHEMBL18759028 0.86 CA14 (0.47) CA14HDAC6HDAC1HDAC2ALDH1A1
SCHEMBL30942676 0.85 CA14 (0.40) CA14HDAC6HDAC1HDAC2
SCHEMBL25459027 0.85 HDAC6 (0.38) CA14HDAC6HDAC1HDAC2ALDH1A1
SCHEMBL224144 0.83 HDAC6 (0.37) CA14HDAC6HDAC1HDAC2ALDH1A1
SCHEMBL412345 0.82 L3MBTL1 (0.40) CA14HDAC6HDAC1HDAC2ALDH1A1
SCHEMBL18759031 0.81 CA14 (0.42) CA14HDAC6HDAC1HDAC2ALDH1A1
SCHEMBL23857521 0.81 CA14 (0.45) CA14HDAC6HDAC1HDAC2L3MBTL1
SCHEMBL20783203 0.80 CA14 (0.41) CA14HDAC6HDAC1HDAC2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230146675-A1 PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS iTeos Belgium SA (BE) 2023-05-11 US disclosed
US-20230146675-A1 PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS iTeos Belgium SA (BE) 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230146675-A1 PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS ENTPD5, ENTPD1, SLC29A1 CA14 4547/4885HDAC6 4322/4885HDAC1 4381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.